ReviewBiomedicines2024
Precision Medicine in Inflammatory Bowel Disease: A Spotlight on Emerging Molecular Biomarkers.
Review in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Interpreting Biomarker Discordance in Inflammatory Bowel Disease: Beyond Fecal Calprotectin and C-Reactive Protein.Biomedicines · 2026Review
- Blunted Cortisol Awakening Response in Patients with Inflammatory Bowel Disease: A Cross-Sectional Case-Control Study.Medical sciences (Basel, Switzerland) · 2026Article
- Microbiota-Derived Metabolites in the Epigenetic Regulation of Redox Homeostasis.Antioxidants (Basel, Switzerland) · 2026Review
- Association Between the C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index and Tissue-Confirmed Cytomegalovirus Colitis in Patients with Active Ulcerative Colitis.Diagnostics (Basel, Switzerland) · 2026Article
- Beyond the Intestinal Mucosa in Long-Standing Inflammatory Bowel Disease: Consequences of Chronic Inflammation and Endoscopic Approaches to Diagnosis and Management.Medicina (Kaunas, Lithuania) · 2026Review
- Diet, Gut Microbiome, and Microbial Metabolites in Inflammatory Bowel Disease: From Functional Dysbiosis to Precision Nutrition.International journal of molecular sciences · 2026Review
- Granzyme B PET Imaging Uncovers Dynamic Patterns of Disease Activity and Therapeutic Response in a Murine Colitis Model.International journal of molecular sciences · 2026Article
- [Advanced Combination Therapy in Inflammatory Bowel Disease].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2026Review
- Prevalence, Clinical Characteristics, and Predictors of Difficult-to-Treat Inflammatory Bowel Disease in a Real-World Taiwanese Cohort.Life (Basel, Switzerland) · 2026Article
- Inflammatory bowel diseases: pathological mechanisms and therapeutic perspectives.Molecular biomedicine · 2026Review
- Article
- Mechanistic remodeling and immunoregulatory functions of the B cell-humoral immunity axis in inflammatory bowel disease.Frontiers in immunology · 2026Review
- Serum Oncostatin M in Ulcerative Colitis Patients and Its Relation to Disease Activity.International journal of molecular sciences · 2025Article
- Precision Medicine in Disorders of Gut-Brain Interaction.Gastroenterology & hepatology · 2025Article
- Engineered Tissue Models to Decode Host-Microbiota Interactions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- State-of-the-Art Evidence for Clinical Outcomes and Therapeutic Implications of Janus Kinase Inhibitors in Moderate-to-Severe Ulcerative Colitis: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Challenges and limitations in assessing mucosal healing in Crohn's disease: Discrepancies between endoscopic and histologic evaluations.World journal of gastrointestinal endoscopy · 2025Article
- Advancing Therapeutic Targets in IBD: Emerging Goals and Precision Medicine Approaches.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Predictive Value of Albumin to Fibrinogen Ratio and CALLY Index for Diagnosis of Ulcerative Colitis and Mucosal Healing After Vedolizumab Treatment.Journal of inflammation research · 2025Article
- Nutritional psychology and inflammatory bowel disease: a narrative review of gut-brain axis interactions.Frontiers in nutrition · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel diseases (IBD) remain challenging in terms of understanding their causes and in terms of diagnosing, treating, and monitoring patients. Modern diagnosis combines biomarkers, imaging, and endoscopic methods. Common biomarkers like CRP and fecal calprotectin, while invaluable tools, have limitations and are not entirely specific to IBD. The limitations of existing markers and the invasiveness of endoscopic procedures highlight the need to discover and implement new markers. With an ideal biomarker, we could predict the risk of disease development, as well as the possibility of response to a particular therapy, which would be significant in elucidating the pathogenesis of the disease. Recent research in the fields of machine learning, proteomics, epigenetics, and gut microbiota provides further insight into the pathogenesis of the disease and is also revealing new biomarkers. New markers, such as BAFF, PGE-MUM, oncostatin M, microRNA panels, αvβ6 antibody, and S100A12 from stool, are increasingly being identified, with αvβ6 antibody and oncostatin M being potentially close to being presented into clinical practice. However, the specificity of certain markers still remains problematic. Furthermore, the use of expensive and less accessible technology for detecting new markers, such as microRNAs, represents a limitation for widespread use in clinical practice. Nevertheless, the need for non-invasive, comprehensive markers is becoming increasingly important regarding the complexity of treatment and overall management of IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.